12.4: FDA Marketing Review and Other Pathways

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    12.4: FDA Marketing Review and Other Pathways

    FDA marketing review infographic (1).pngA sponsor seeking approval for a proposed use generally submits a new drug application (NDA) or a biologics license application (BLA). FDA weighs the benefits and risks, reviews the proposed labeling, and evaluates whether the manufacturing process and facilities can consistently supply a product that meets applicable requirements.

    A BLA requests FDA licensure of a biological product under the Public Health Service Act. It includes evidence supporting safety, purity, and potency, along with manufacturing and facility information. FDA’s CBER or CDER reviews the application, depending on the product. Biosimilars use a separate abbreviated BLA pathway and are not approved through ANDAs.

    Within the FDA, the Center for Drug Evaluation and Research (CDER) reviews most human drugs and many therapeutic biologics. The Center for Biologics Evaluation and Research (CBER) oversees products such as vaccines and many cell and gene therapies. The USDA has separate responsibilities, including oversight of many veterinary biologics.

    Generic and Over-the-Counter Drugs

    A manufacturer typically applies to market a generic drug through an abbreviated new drug application (ANDA). FDA can rely on its previous finding of safety and effectiveness for the reference drug. The generic applicant still provides evidence on the product’s composition, manufacturing controls, labeling, and bioequivalence or an applicable waiver.

    Bioavailability describes how quickly and how much of an active ingredient or active moiety becomes available at its site of action. Bioequivalence compares that rate and extent for products given at the same molar dose under similar conditions. The right test depends on where and how the drug works. Blood levels may be less informative for a drug that acts locally.

    Nonprescription, or over-the-counter (OTC), drugs may be marketed through an approved application or under the OTC monograph framework when all applicable conditions are met. The CARES Act of 2020 modernized the monograph system through an administrative order process. Applicable orders describe conditions such as ingredients, doses, uses, warnings, and labeling. A conforming monograph drug generally does not need an individually approved application, but manufacturing, labeling, registration, listing, and other requirements still apply.

    Review Programs and Designations FDA review programs and designations.png

    Priority review — FDA gives additional attention to applications for drugs that, if approved, would offer significant improvements in the treatment, diagnosis, or prevention of serious conditions. The review goal is shorter than for standard review. Priority review does not lower approval standards.

    Orphan drug designation — Supports development of drugs and biologics for rare diseases. A rare disease generally affects fewer than 200,000 people in the United States, although an alternative cost-recovery criterion exists. Designation is separate from marketing approval.

    Potential orphan drug incentives include tax credits for qualifying clinical testing, certain fee exemptions, access to grants, and seven years of orphan drug exclusivity after qualifying approval. Eligibility and limitations apply. Designation does not guarantee approval, a grant, or exclusivity for every use of the product.

    Accelerated approval — Allows approval for certain serious conditions based on a surrogate endpoint, or an intermediate clinical endpoint, reasonably likely to predict clinical benefit. Required confirmatory studies assess the anticipated benefit. FDA can withdraw approval if benefit is not verified or other requirements are not met.

    Fast track — Facilitates development and review of drugs intended for serious conditions that address unmet medical needs. Breakthrough therapy designation is another expedited program; it requires preliminary clinical evidence suggesting substantial improvement over available therapy on a clinically significant endpoint.

    Tentative approval — Indicates that an application meets applicable approval requirements but cannot yet receive final approval because of a patent or exclusivity barrier. It does not authorize U.S. marketing. Final approval is required before marketing under that application.

    Three-panel animal facts infographic.pngAccelerated approval also requires careful interpretation. An effect on a surrogate endpoint may support an expectation of clinical benefit, but the two are not identical. For example, a laboratory measurement may change before researchers know whether people feel better, function better, or live longer. The relationship must be scientifically supported for the particular setting, and the required follow-up evidence remains important.

    The Animal Rule

    The Animal Rule allows FDA to rely on adequate and well-controlled animal studies for evidence of effectiveness in certain serious conditions when human efficacy studies are unethical and field trials are not feasible. Human safety must still be established. The requirements appear in 21 CFR Parts 314, Subpart I, and 601, Subpart H. This is not a general exemption for drugs or vaccines, and orphan designation does not waive safety or effectiveness standards.


    This page titled 12.4: FDA Marketing Review and Other Pathways was last modified on Sun, 08 Nov 2026 14:20:49 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.